Abstract:American Journal of HematologyVolume 98, Issue 5 p. E106-E109 CORRESPONDENCEFree Access Ruxolitinib combined with dexamethasone in adult patients with newly diagnosed Hemophagocytic lymphohistiocytosis: A single-center pilot trial De Zhou, De Zhou orcid.org/0000-0002-3698-2750 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXianbo Huang, Xianbo Huang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorMixue Xie, Mixue Xie Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorLixia Zhu, Lixia Zhu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXin Huang, Xin Huang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXueying Li, Xueying Li orcid.org/0000-0002-9609-1984 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXiudi Yang, Xiudi Yang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorLi Li, Li Li Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJingjing Zhu, Jingjing Zhu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXiaolong Zheng, Xiaolong Zheng Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJianai Sun, Jianai Sun Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorShuqi Zhao, Shuqi Zhao Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorWenjuan Yu, Wenjuan Yu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorWanzhuo Xie, Wanzhuo Xie orcid.org/0000-0002-0966-5581 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorHongyan Tong, Hongyan Tong orcid.org/0000-0001-5603-4160 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJie Jin, Corresponding Author Jie Jin [email protected] orcid.org/0000-0002-8166-9915 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this authorHonghu Zhu, Corresponding Author Honghu Zhu [email protected] orcid.org/0000-0003-2343-0436 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this authorXiujin Ye, Corresponding Author Xiujin Ye [email protected] orcid.org/0000-0002-4553-2751 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], zhuhhd[email protected], [email protected]Search for more papers by this author De Zhou, De Zhou orcid.org/0000-0002-3698-2750 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXianbo Huang, Xianbo Huang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorMixue Xie, Mixue Xie Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorLixia Zhu, Lixia Zhu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXin Huang, Xin Huang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXueying Li, Xueying Li orcid.org/0000-0002-9609-1984 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXiudi Yang, Xiudi Yang Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorLi Li, Li Li Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJingjing Zhu, Jingjing Zhu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorXiaolong Zheng, Xiaolong Zheng Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJianai Sun, Jianai Sun Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorShuqi Zhao, Shuqi Zhao Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorWenjuan Yu, Wenjuan Yu Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorWanzhuo Xie, Wanzhuo Xie orcid.org/0000-0002-0966-5581 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorHongyan Tong, Hongyan Tong orcid.org/0000-0001-5603-4160 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR ChinaSearch for more papers by this authorJie Jin, Corresponding Author Jie Jin [email protected] orcid.org/0000-0002-8166-9915 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this authorHonghu Zhu, Corresponding Author Honghu Zhu [email protected] orcid.org/0000-0003-2343-0436 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this authorXiujin Ye, Corresponding Author Xiujin Ye [email protected] orcid.org/0000-0002-4553-2751 Department of Hematology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, PR China Zhejiang Provincial Key Lab of Hematopoietic Malignancy, Zhejiang University, Hangzhou, PR China Institute of Hematology, Zhejiang University, Hangzhou, PR China Correspondence Jie Jin, Honghu Zhu and Xiujin Ye, Department of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, No.79 Qingchun Road, Shangcheng District, Hangzhou City 310003, Zhejiang Province, China. Email: [email protected], [email protected], [email protected]Search for more papers by this author First published: 15 February 2023 https://doi.org/10.1002/ajh.26877 De Zhou, Xianbo Huang and Mixue Xie contributed equally to the work. AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL To the Editor: Hemophagocytic lymphohistiocytosis (HLH) is a rapidly progressive and life-threatening disease that can be classified into primary and secondary HLH, most adult patients have secondary HLH, and the main secondary causes are infection, rheumatic disease, and malignancy. The current first-line treatment regimen such as HLH-94 or HLH-2004 are largely extrapolated from pediatric HLH; however, the prognosis of adult HLH is worse than that of children.1, 2 In addition to its unsatisfactory efficacy, the toxicity of HLH-94/HLH-2004 regimens has resulted in relatively high treatment-related mortality,2 Therefore, more efficient and less toxic induction therapy is needed in secondary HLH. Excessive production of cytokines contributes to the pathogenesis of HLH. Recent studies have indicated that ruxolitinib, a small-molecule inhibitor of Janus kinases (JAKs), which are essential for cytokine signaling, may be therapeutic in HLH. A prospective study demonstrated that ruxolitinib is effective and safe in adults with secondary HLH,3 and all patients responded to ruxolitinib and survived for more than two months. Moreover, Lauren K. Meyer et al.4 demonstrated that hypercytokinemia of HLH reduces the apoptotic potential of CD8+ T cells, leading to relative dexamethasone resistance, and this apoptotic potential is restored both in vitro and in vivo upon exposure to ruxolitinib. Based on the above studies, we performed this single-center, pilot study to evaluate the efficacy and tolerability of Ru-D in adult patients with secondary HLH at the First Affiliated Hospital, College of Medicine, Zhejiang University. Patients enrolled in this study met the following criteria: (1) fulfilled at least five of the eight HLH-2004 criteria for HLH; (2) male or female, older than 18 years; (3) no prior chemotherapy treatment for HLH; and (4) signed an informed consent form before participating in the study. Patients who met any one of the following were ineligible: central nervous system involvement, presence of a malignancy, HIV infection, and pregnant women. Patients in this study underwent an 8-week period of treatment. The Ru-D regimen consists of ruxolitinib (15 mg twice daily for 8 weeks) and dexamethasone (initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering). For follow-up and salvage treatment, we employed the following criteria: (1) If patients did not respond to the Ru-D regimen after 7 days or relapsed at any point during treatment, they entered a rescue regimen such as HLH-94 or doxorubicin-etoposide-methylprednisolone (DEP); (2) If patients were diagnosed with lymphoma after enrollment, chemotherapy was immediately started; (3) After 8 weeks of treatment, if no recurrence and no HLH-related gene mutations were detected, treatment was discontinued, and these patients entered the follow-up stage; (4) Allo-HSCT was performed in patients who met the criteria for allo-HSCT. The primary endpoint was the overall response during treatment with the Ru-D regimen in this study. The overall response rate (ORR) included the percentage of patients with a complete response (CR), a partial response (PR), or an improvement in the measures of HLH. Efficacy was evaluated 7, 14, 28, and 56 days after initiating Ru-D therapy. The efficacy of treatment was assessed according to the evaluation criteria proposed by Franco et al5 Secondary endpoints were safety and tolerability, progression-free survival (PFS), overall survival (OS), and changes in biomarkers between baseline and post-treatment. Adverse events in this study were assessed according to the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0 (CTCAE 5.0). From April 1, 2021 to May 31, 2021, a total of 8 patients were enrolled in this study. The main clinical characteristics of the patients enrolled are summarized in Table 1. All the patients were adults, and the median age was 48 years (range 23–77 years). Among the 8 patients, five were eventually diagnosed with lymphoma-associated HLH (LAHS) after enrollment. The remaining three included one bacterial infection-associated HLH and two cases of Epstein–Barr virus-associated HLH (EVB-HLH). Serum EBV-DNA copies were positive in seven patients (102–106 copies/mL) and were negative in the patient who was diagnosed with bacterial infection-associated HLH. The eight patients had ECOG performance status scores of 2 to 4, and most patients were steady at 3 or 4. TABLE 1. Baseline characteristics and response of enrolled patients. Clinical features Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Patient 7 Patient 8 Age(years) 37 39 54 69 76 77 42 23 Gender Female Male Male Female Female Female Female Male ECOG score 2 4 3 3 3 3 2 4 Previous therapies IVIG, antibiotics, antivirals, corticosteroid IVIG, antibiotics, corticosteroid Antibiotics, antivirals, corticosteroid Antibiotics, corticosteroid Antibiotics Antibiotics Antibiotics, corticosteroid Antibiotics, corticosteroid Etiology NKTCL Bacterial infections DLBCL PTCL EBV-HLH PTCL EBV-HLH NKTCL Fever Yes Yes Yes Yes Yes Yes Yes Yes Splenomegaly Yes No Yes Yes No No Yes Yes Absolute neutrophil count (×109/L) 1.3 12.07 4.76 0.8 1.7 0.5 0.9 0.6 Hemoglobin concentration (g/L) 77 113 121 82 89 124 81 92 Absolute platelet count (×109/L) 32 282 81 89 67 23 31 3 Triglyceride concentration (mmol/L) 3.14 1.94 2.03 1.06 1.25 3.38 2.31 4.43 Fibrinogen concentration (g/L) 1.05 3.67 6.78 0.96 1.48 1.8 0.5 1.28 Ferritin concentration (μg/L) 1151.8 19176.6 4222.6 2299.4 32847.2 20241.4 5156.3 >40 000 Hemophagocytosis in bone marrow Yes Yes No No Yes Yes Yes Yes Natural killer cell activity (%) 21.05 6.95 14.84 — — — 16.44 14.48 Natural killer cell CD107a (%) 10.44 0.99 3.49 — — — 4.56 1.52 Soluble CD25 (pg/mL) 58 240 20 917 78 770 — — — 13 437 43 403 HLH-2004 criteria 7/8 6/8 5/8 5/8a 5/8a 5/8a 7/8 8/8 EBV-DNA (copies/mL) 3.29 × 106 Negative 9.20 × 102 2.58 × 103 1.23 × 103 9.34 × 102 3.31 × 103 9.47 × 106 Treatment days 26 56 14 52 56 20 56 2 Best Response PR CR Improvement in measures of HLH CR CR PR CR NR Duration of Response (days) 26 269 141 52 244 20 234 — Survival No Yes No No Yes No Yes No Survival time (days) 175 450 141 332 425 20 415 2 Reason for death Progression of lymphoma — CRPA infection Relapse of lymphoma — Bronchiectasis with massive hemoptysis — Progression of HLH Note: Normal reference range: Ferritin concentration < 500 μg/L, Triglyceride concentration 1.70 < mmol/L, Fibrinogen concentration 2.0 ~ 4.0 g/L, soluble CD25 ≤ 6400 pg/mL, soluble CD163 88 ~ 902 pg/mL, Natural killer cell activity≥15.11%, Natural killer cell CD107a ≥ 10%. Abbreviations: CR, complete response; CRPA, carbapenem-resistant pseudomonas aeruginosa; DLBCL, diffuse large B-cell lymphoma; EBV, Epstein–Barr virus; ECOG, Eastern Cooperative Oncology Group; IVIG, intravenous immunoglobulin; NKTCL, NK/T-cell lymphoma; NR, no response; PTCL, peripheral T-cell lymphoma. a Natural killer cell activity and Soluble CD25 were not tested. Patients were followed up until June 30, 2022 or until death, with none lost to follow-up. Table 1 also shows the response outcomes in detail. The median follow-up time was 8.5 (range, 0.1–15.0) months. The ORR to the Ru-D regime was 87.5% (7/8), with 50% (4/8) showing CR, 25.0% (2/8) PR, and 12.5% (1/8) improvement in measures of HLH, 12.5% (1/8) no response (NR). Among the LAHS patients, one patient (20%) achieved CR, two patients (40%) achieved PR, and 1 patient (20%) achieved improvement in measures of HLH, and 1 patient (20%) NR. All the 3 non-LAHS patients achieved CR, and no recurrence has occurred so far. The OS was 75% (6/8) at 2 months, 50% (4/8) at 6 months and 37.5% at 12 months. Although the overall mortality rate was 62.5% (5/8), there was only one death directly related to HLH. The Ru-D treatment in our study was well tolerated, with no toxicities leading to dose reduction or discontinuation of treatment observed. Ruxolitinib has been reported to have a risk of hematological toxicity, which is difficult to evaluate because cytopenia is also the major clinical feature of HLH. We found that only 1 patient (12.5%) had grade III anemia during Ru-D therapy. Four additional patients (50%) developed grade II hematologic toxicity. Regarding infections, pneumocystis pneumonia (PCP) occurred in Patient 7 after 56 days of Ru-D treatment and was successfully cured by trimethoprim-sulfamethoxazole. Patient 6 had a history of baseline bronchiectasis and chronic pulmonary infection with PA before receiving Ru-D. During treatment, this patient suffered aggravation of pulmonary infection and presented with cough, sputum, and inflammatory exudation changes on lung imaging and positive sputum culture for PA, while the body temperature remained within normal limits. She was treated with cefoperazone-sulbactam against PA but had poor control of the infection, developed massive hemoptysis on Day 19, and died in 48 hours. For other patients, no unusual infections were observed. Secondary HLH in adults is a major clinical challenge due to its rapid progression and high mortality. The current first-line treatment strategies are the HLH-94 and HLH-2004 regimens, the ORR was approximately 70%. There were 8 patients enrolled in our study, whose ORR was 87.5%, which is higher than the patients treated with the HLH-94/HLH-2004 regimen. The survival of adult patients with HLH is poor, in a large, multicenter, retrospective study, the median OS in patients with malignancy-associated HLH was 2.8 months and for those with non-malignancy-associated HLH was 10.7 months.3 We also have retrospectively analyzed 205 patients seen between January 2011 and December 2015 in our hospital. The median OS was only 1.8 months, and most of these patients received HLH-94 as initial treatment.6 In this study, the median OS was 4.7 months in patients with LAHS, and all the patients with non-LAHS are now alive with a CR status for more than one year. In contrast to the above studies, this study demonstrated better short-term survival in both malignancy-associated HLH and non-malignancy-associated HLH patients. In our study, Ru-D regimen shows that it is an efficient and safe initial treatment for patients with LAHS, the rapid control of cytokine-driven inflammation gives these patients opportunity to confirm the diagnosis of lymphoma and bridge to chemotherapy. Although Ru-D regimen may improve short-term survival in LAHS patients, their long-term survival remains poor. More effective anti-lymphoma strategies may be the fundamental way to improve the prognosis of these patients. Overall, the Ru-P regimen was well tolerated in this study. Regarding hematologic toxicity, only 1 patient (25%) developed grade III hematologic toxicity. The peripheral blood cell counts of patients who responded gradually improved during Ru-D treatment. However, it should be noted that during Ru-D treatment, we found 2 cases of grade III or higher infection-related AE. Therefore, during Ru-D treatment, we should be aware of the aggravation of the original infection and new opportunistic infections. More experience is needed to assess the need for prophylactic anti-infective therapy in these patients. In summary, this study was a preliminary attempt at giving the Ru-D regimen to newly diagnosed adult HLH patients. Although the sample size was small and the follow-up time was relatively short. Given the rarity and high short-term mortality of adult HLH, the results of this study have some relevance indeed. Ru-D showed a high ORR and good safety and has the potential to become a first-line treatment for HLH in adults. AUTHOR CONTRIBUTIONS De Zhou, Honghu Zhu, Jie Jin, Xiujin Ye, and Xianbo Huang designed the study; De Zhou, Xianbo Huang, and Mixue Xie analyzed the results; De Zhou and Xianbo Huang wrote the paper; De Zhou, Xiu jin Ye, Xianbo Huang, and Xueying Li performed the research; Xin Huang, Xiudi Yang, Li LI, Lixia Zhu, Jingjing Zhu, Xiaolong Zheng, Jianai Sun, Shuqi Zhao, Wenjuan Yu, Wanzhuo Xie, and Hongyan Tong collected the data and reviewed the paper. De Zhou, Xiujin Ye, and Xianbo Huang obtained funding. Honghu Zhu and Jie Jin provided administrative support. All authors read and approved the final manuscript. ACKNOWLEDGMENTS The authors thank the patients and their families, and medical staff who participated in this study. This work was supported by grants from Zhejiang Provincial Natural Science Foundation of China (No. LGF22H160040 and LZ22H080002), and Natural Science Foundation of China (No. 81900152). The funder of the study had no role in the study design, data collection, data analysis, data interpretation, or writing of the report. CONFLICT OF INTEREST STATEMENT The authors declare no conflict of interest. Open Research DATA AVAILABILITY STATEMENT The data that support the findings of this study are available from the corresponding author upon reasonable request. REFERENCES 1Schram AM, Comstock P, Campo M, et al. Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years. Br J Haematol. 2016; 172: 412- 419. 2Henter JI, Samuelsson-Horne A, Arico M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002; 100: 2367- 2373. 3Ahmed A, Merrill SA, Alsawah F, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-Centre, pilot trial. Lancet Haematol. 2019; 6(12):e630-e637. 4Meyer LK, Verbist KC, Albeituni S, et al. JAK/STAT pathway inhibition sensitizes CD8 T cells to dexamethasone-induced apoptosis in hyperinflammation. Blood. 2020; 136(6): 657- 668. 5Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary Hemophagocytic Lymphohistiocytosis. N Engl J Med. 2020; 382(19): 1811- 1822. 6Zhou M, Li L, Zhang Q, et al. Clinical features and outcomes in secondary adult hemophagocytic lymphohistiocytosis. Int J Med. 2018; 111: 23- 31. Volume98, Issue5May 2023Pages E106-E109 ReferencesRelatedInformation

Abstract:Article23 January 2020free access UHMK1 promotes gastric cancer progression through reprogramming nucleotide metabolism Xing Feng orcid.org/0000-0001-8226-3389 The Affiliated Hospital of Guilin Medical University, Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guangxi Neurological Diseases Clinical Research Center, Guilin, Guangxi, China Department of Immuobiology, Yale University School of Medicine, New Haven, CT, USA Search for more papers by this author Dong Ma Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China Search for more papers by this author Jiabao Zhao Department of Gastrointestinal Surgery, Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, China Search for more papers by this author Yongxi Song Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, China Search for more papers by this author Yuekun Zhu Medical Center, Duke University, Durham, NC, USA Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China Search for more papers by this author Qingxin Zhou Department of Oncology, The Third Affiliated Hospital of Harbin Medical University, Harbin, China Search for more papers by this author Fei Ma Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China Search for more papers by this author Xing Liu Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China Search for more papers by this author Mengya Zhong Department of Gastrointestinal Surgery, Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, China Search for more papers by this author Yu Liu Department of Gastrointestinal Surgery, Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, China Search for more papers by this author Yubo Xiong Department of Gastrointestinal Surgery, Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, China Search for more papers by this author Xingfeng Qiu Department of Gastrointestinal Surgery, Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, China Search for more papers by this author Zhen Zhang Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Anhui, China Search for more papers by this author Heng Zhang Department of Histology and Embryology, Xiang Ya School of Medicine, Central South University, Changsha, China Search for more papers by this author Yongxiang Zhao National Center for International Research of Biological Targeting Diagnosis and Therapy (Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research), Guangxi Medical University, Nanning, China Search for more papers by this author Kaiguang Zhang Corresponding Author [email protected] orcid.org/0000-0001-9462-6335 Department of Digestive Disease, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, University of Science and Technology of China, Anhui, China Search for more papers by this author Xuehui Hong Corresponding Author [email protected] [email protected] orcid.org/0000-0002-8853-7384 Department of Gastrointestinal Surgery, Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, China Search for more papers by this author Zhiyong Zhang Corresponding Author [email protected] [email protected] orcid.org/0000-0003-4061-7374 The Affiliated Hospital of Guilin Medical University, Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guangxi Neurological Diseases Clinical Research Center, Guilin, Guangxi, China Department of Surgery, Robert-Wood-Johnson Medical School University Hospital, Rutgers University, The State University of New Jersey, New Brunswick, NJ, USA Search for more papers by this author Xing Feng orcid.org/0000-0001-8226-3389 The Affiliated Hospital of Guilin Medical University, Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guangxi Neurological Diseases Clinical Research Center, Guilin, Guangxi, China Department of Immuobiology, Yale University School of Medicine, New Haven, CT, USA Search for more papers by this author Dong Ma Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China Search for more papers by this author Jiabao Zhao Department of Gastrointestinal Surgery, Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, China Search for more papers by this author Yongxi Song Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, China Search for more papers by this author Yuekun Zhu Medical Center, Duke University, Durham, NC, USA Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China Search for more papers by this author Qingxin Zhou Department of Oncology, The Third Affiliated Hospital of Harbin Medical University, Harbin, China Search for more papers by this author Fei Ma Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China Search for more papers by this author Xing Liu Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China Search for more papers by this author Mengya Zhong Department of Gastrointestinal Surgery, Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, China Search for more papers by this author Yu Liu Department of Gastrointestinal Surgery, Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, China Search for more papers by this author Yubo Xiong Department of Gastrointestinal Surgery, Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, China Search for more papers by this author Xingfeng Qiu Department of Gastrointestinal Surgery, Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, China Search for more papers by this author Zhen Zhang Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Anhui, China Search for more papers by this author Heng Zhang Department of Histology and Embryology, Xiang Ya School of Medicine, Central South University, Changsha, China Search for more papers by this author Yongxiang Zhao National Center for International Research of Biological Targeting Diagnosis and Therapy (Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research), Guangxi Medical University, Nanning, China Search for more papers by this author Kaiguang Zhang Corresponding Author [email protected] orcid.org/0000-0001-9462-6335 Department of Digestive Disease, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, University of Science and Technology of China, Anhui, China Search for more papers by this author Xuehui Hong Corresponding Author [email protected] [email protected] orcid.org/0000-0002-8853-7384 Department of Gastrointestinal Surgery, Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, China Search for more papers by this author Zhiyong Zhang Corresponding Author [email protected] [email protected] orcid.org/0000-0003-4061-7374 The Affiliated Hospital of Guilin Medical University, Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guangxi Neurological Diseases Clinical Research Center, Guilin, Guangxi, China Department of Surgery, Robert-Wood-Johnson Medical School University Hospital, Rutgers University, The State University of New Jersey, New Brunswick, NJ, USA Search for more papers by this author Author Information Xing Feng1,2,‡, Dong Ma3,‡, Jiabao Zhao4,‡, Yongxi Song5,‡, Yuekun Zhu6,7, Qingxin Zhou8, Fei Ma9, Xing Liu10, Mengya Zhong4, Yu Liu4, Yubo Xiong4, Xingfeng Qiu4, Zhen Zhang11, Heng Zhang12, Yongxiang Zhao13, Kaiguang Zhang *,14, Xuehui Hong *,*,4,‡ and Zhiyong Zhang *,*,1,15,‡ 1The Affiliated Hospital of Guilin Medical University, Guangxi Key Laboratory of Brain and Cognitive Neuroscience, Guangxi Neurological Diseases Clinical Research Center, Guilin, Guangxi, China 2Department of Immuobiology, Yale University School of Medicine, New Haven, CT, USA 3Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, China 4Department of Gastrointestinal Surgery, Zhongshan Hospital, School of Medicine, Xiamen University, Xiamen, China 5Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Shenyang, China 6Medical Center, Duke University, Durham, NC, USA 7Department of General Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, China 8Department of Oncology, The Third Affiliated Hospital of Harbin Medical University, Harbin, China 9Department of General Surgery, The Second Affiliated Hospital of Harbin Medical University, Harbin, China 10Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, China 11Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Anhui, China 12Department of Histology and Embryology, Xiang Ya School of Medicine, Central South University, Changsha, China 13National Center for International Research of Biological Targeting Diagnosis and Therapy (Guangxi Key Laboratory of Biological Targeting Diagnosis and Therapy Research), Guangxi Medical University, Nanning, China 14Department of Digestive Disease, The First Affiliated Hospital of USTC, Anhui Provincial Hospital, University of Science and Technology of China, Anhui, China 15Department of Surgery, Robert-Wood-Johnson Medical School University Hospital, Rutgers University, The State University of New Jersey, New Brunswick, NJ, USA ‡These authors contributed equally to this work ‡These authors contributed equally to this work as senior authors *Corresponding author. Tel: +86 551 62283114; Fax: +86 551 62283114; E-mail: [email protected] *Corresponding author. Tel: +86 592 2993182; Fax: +86 592 2993182; E-mails: [email protected]; [email protected] *Corresponding author. Tel: +1 732 2356853; Fax: +1 732 2356853; E-mails: [email protected]; [email protected] EMBO J (2020)39:e102541https://doi.org/10.15252/embj.2019102541 PDFDownload PDF of article text and main figures. Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinked InMendeleyWechatReddit Figures & Info Abstract UHMK1 is a nuclear serine/threonine kinase recently implicated in carcinogenesis. However, the functions and action mechanisms of UHMK1 in the pathogenesis of human gastric cancer (GC) are unclear. Here, we observed that UHMK1 was markedly upregulated in GC. UHMK1 silencing strongly inhibited GC aggressiveness. Interestingly, UHMK1-induced GC progression was mediated primarily via enhancing de novo purine synthesis because inhibiting purine synthesis reversed the effects of UHMK1 overexpression. Mechanistically, UHMK1 activated ATF4, an important transcription factor in nucleotide synthesis, by phosphorylating NCOA3 at Ser (S) 1062 and Thr (T) 1067. This event significantly enhanced the binding of NCOA3 to ATF4 and the expression of purine metabolism-associated target genes. Conversely, deficient phosphorylation of NCOA3 at S1062/T1067 significantly abrogated the function of UHMK1 in GC development. Clinically, Helicobacter pylori and GC-associated UHMK1 mutation induced NCOA3-S1062/T1067 phosphorylation and enhanced the activity of ATF4 and UHMK1. Importantly, the level of UHMK1 was significantly correlated with the level of phospho-NCOA3 (S1062/T1067) in human GC specimens. Collectively, these results show that the UHMK1-activated de novo purine synthesis pathway significantly promotes GC development. Synopsis This study delineates a new role for the nuclear serine/threonine kinase UHMK1 as driver of gastric cancer (GC) via regulating purine metabolism and NCOA3/ATF4-mediated gene expression control. Levels of UHMK1 and NCOA3 phosphorylation are promising stratifiers for patient outcome. UHMK1 expression is significantly upregulated in GC and correlates with poor clinical outcome. UHMK1 directly phosphorylates NCOA3 at Ser1062 and Thr1067 residues. NCOA3-S1062/T1067 phosphorylation promotes ATF4 binding, expression of purine metabolic target genes, and GC progression. Helicobacter pylori infection and GC-related UHMK1 mutation (M134T and T217K) enhance NCOA3-S1062/T1067 phosphorylation, activity of ATF4 and UHMK1. Introduction Gastric cancer (GC) has been indicated to be one of the deadliest malignancies. Helicobacter pylori (H. pylori) infection, dietary habits, and other environmental risk agents contribute greatly to GC development (Wroblewski et al, 2010). Although surgical resection is a primary therapeutic option for GC patients, the 5-year survival rate remains approximately 30.6% but is only 5.2% for patients with advanced stages (Yusefi et al, 2018). Therefore, a better understanding of molecular aberrations involved in GC pathogenesis is necessary to improve the clinical outcomes of GC patients. U2AF homology motif kinase 1 (UHMK1) is a ubiquitously expressed nuclear serine (Ser, S)/threonine (Thr, T) kinase (Francone et al, 2010). It was initially identified to regulate the function of stathmin (Barbutti et al, 2017). Since then, UHMK1 has been indicated to bind a range of proteins, such as eEF1A, FAM64, cyclin-dependent kinase inhibitor (CDKI), p27KIP1, SF3b155, and CPEB1, suggesting the varied roles of UHMK1 in different cellular processes (Manceau et al, 2008; Cambray et al, 2009). Although UHMK1 dysregulation or mutation has been recently indicated to be a high-penetrant factor in different types of human tumors, such as pancreatic and ovarian cancer (Katchman et al, 2017; Grant et al, 2018; Wang et al, 2018), its effect and action mechanisms in most cancers including GC still were uncovered. Tumor cells reprogram glucose metabolism by switching from oxidative phosphorylation (OXPHOS) to a process termed the Warburg effect (Song et al, 2014). However, emerging evidence indicates that dysregulated purine metabolism is implicated in tumors (Nishimura et al, 2019). This finding is not surprising, because many metabolites from the Warburg effect or pentose phosphate pathway (PPP) are essential carbon sources for purine biosynthesis (Hong et al, 2014). Several kinases and transcription factors (TFs), for example, mechanistic target of rapamycin kinase (mTOR), activating transcription factor 4 (ATF4), microphthalmia-associated transcription factor (MITF), and c-Myc, dictate cancer-dependent purine biosynthesis (Ben-Sahra et al, 2016; Karigane et al, 2016). We recently reported that dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 3 (Dyrk3) inhibited liver cancer by downregulating purine synthesis (Ma et al, 2019). However, the effect of purine metabolism on GC is not clear. Herein, by analyzing data from The Cancer Genome Atlas (TCGA) and Oncomine database, we found that genomic DNA of UHMK1 was frequently amplified in GC. Therefore, we further investigated the role and mechanism of UHMK1 in GC. We found that upregulation of UHMK1 suggested poor prognosis of GC patients. We demonstrated that UHMK1 functioned as an oncogene mainly by promoting the purine synthesis pathway in GC. Therefore, UHMK1-enhanced nucleotide synthesis might be an important therapeutic target in GC. Results High-level UHMK1 expression is strongly correlated with GC aggressiveness We first examined the functions of UHMK1 in GC by investigating the relative levels of UHMK1 in five paired GC patient tissues and corresponding normal tissues. The amount of UHMK1 was significantly increased in GC tissues compared with control tissues (Fig 1A). In addition, the amount of UHMK1 in most GC cell lines was often higher than that in the GES-1 cell line, a normal gastric epithelial cell line (Fig 1B). Similar results were found in other studies of GC in TCGA and Oncomine datasets (Fig EV1A–F). The tissue array analysis results indicated that compared to normal tissues, GC tissues presented increased expression levels of UHMK1 (Fig 1C) and that the percentage of cells with UHMK1 expression in patients with stage I, II, III, and IV GC was 18.2, 36.4, 69, and 100, respectively (Fig 1D), further implying that the level of UHMK1 is strongly correlated with GC malignancy. Analysis of 100 patients with GC confirmed that the level of UHMK1 was strongly associated with tumor status, stage, and lymph node metastasis (Fig 1E and Appendix Table S1). Kaplan–Meier analysis of two independent cohorts indicated that GC patients with higher amounts of UHMK1 presented shorter disease-free survival (DFS) and overall survival (OS) times (Figs 1F and EV1G and H). Multivariate analyses identified UHMK1 as an independent prognostic factor in GC (Appendix Table S2). Collectively, our data reveal that UHMK1 may promote the pathogenesis of GC. Figure 1. High expression of UHMK1 predicts poor prognosis of GC patients A. UHMK1 levels in tumor tissues (T) and corresponding nontumor tissues (N) from five GC patients were analyzed using Western blotting and qRT–PCR. The relative mRNA expression of UHMK1 was presented as mean ± standard deviation from three replicates. Pairwise two-tailed statistical significance was assessed by Student's t-test. B. Immunoblotting and qRT–PCR were used to measure the levels of UHMK1 in GES-1 and GC cell lines. The relative mRNA expression of UHMK1 was presented as mean ± standard deviation from three replicates. Pairwise two-tailed statistical significance was assessed by Student's t-test. C. IHC analysis of UHMK1 expression in a GC patient tissue array (n = 102). Representative images are shown. Scale bars = 100 μm. D. The IHC signals were scored using the Allred score as described in Material and Methods. Data were shown as mean ± standard deviation from three independent experiments. E. UHMK1 expression in 100 GC patients was analyzed based on the following parameters: tumor stage, tumor status, and lymph node invasion status. Fisher's test was applied to calculate the exact P value. F. Patients with GC were stratified by the UHMK1 level (n = 100); OS and DFS were assessed by Kaplan–Meier analysis. Data information: *P < 0.05, **P < 0.01, ***P < 0.001. Download figure Download PowerPoint Click here to expand this figure. Figure EV1. TCGA and Oncomine analysis of UHMK1 expression in GC patients A. TCGA analyzing the levels of UHMK1 in GC patients. *P < 0.05. The central line stands for the median expression of UHMK1. Upper line stands for upper limit (Upper quartile +1.5 interquartile range). Lower line stands for lower limit (lower quartile –1.5 interquartile range). B–F. Analysis of UHMK1 expression from Oncomine database. The central line stands for the median expression of UHMK1. Upper line stands for upper limit (Upper quartile +1.5 interquartile range). Lower line stands for lower limit (lower quartile –1.5 interquartile range) (three biological replicates). G, H. Kaplan–Meier analysis from the second independent cohort of GC patients indicated that patients with higher levels of UHMK1 had shorter OS (G) and DFS (H). Survival curves were plotted according to Kaplan–Meier method, with the log-rank test applied for comparison. Download figure Download PowerPoint UHMK1 knockdown strongly inhibits the proliferation and invasion of GC cells, possibly via metabolic pathway reprogramming To elucidate the functions of UHMK1 in GC, three lentivirus-mediated UHMK1-specific short hairpin RNAs (shRNAs) were transfected to knock down endogenous UHMK1 in two GC cell lines. shUHMK1-#1 and shUHMK1-#2, with high inhibition rates, were selected for further experiments (Fig 2A). UHMK1 deficiency significantly reduced GC cell proliferation, colony formation, migration, and invasion relative to the corresponding levels in negative control cells (Figs 2B and C, and EV2A–F). However, reintroduction of a shRNA-resistant UHMK1 construct, UHMK1Δ, significantly reversed these phenotypes in SGC7901-shUHMK1-#1 or MGC803-shUHMK1-#1 cells (Figs 2B and C, and EV2A–F). Consistent with this result, UHMK1 overexpression in BGC823 and HGC27 cells markedly promoted their proliferative and invasive abilities (Fig EV2G–M). Figure 2. UHMK1 knockdown strongly suppresses the proliferative and invasive abilities of GC cells, possibly via metabolic pathway reprogramming A–C. (A) GC cells (SGC7901 and MGC803) were transfected with (A) shUHMK1-#1, shUHMK1-#2, shUHMK1-#3, or control shRNA lentiviral vector or (B) with a shRNA-resistant expression construct, UHMK1Δ. Western blotting was used to measure the levels of UHMK1. NIH ImageJ software was used to quantify the band intensity. Western blotting assay was conducted for three replicates. (B and C) SGC7901 cells were transfected with or without shUHMK1-#1 or the shRNA-resistant expression construct UHMK1Δ. CCK-8 and colony formation assays were conducted. Scale bars = 5 mm. D, E. The volumes of subcutaneous gastric tumors derived from SGC7901 cells in NOD/SCID mice were determined at different time points. Tumors and representative bioluminescence images are also shown. UHMK1 silencing in the mouse model was confirmed by Western blotting (three biological replicates). Data were presented as mean ± standard deviation from shcontrol and shUHMK1-#1 mice (n = 10 mice/group). Unpaired two-tailed statistical significance was assessed by Student's t-test. Scale bars = 1 cm. F, G. UHMK1 silencing (F) and overexpression (G) affected GC cell abdominal metastasis. The quantitative number of metastatic nodules (left panel) in nude mice (n = 10 mice/group). Representative images of abdominal metastases are also shown (right panel). Scale bars = 1 cm. H. Heatmap of the top 500 genes upregulated in GC patients with high UHMK1 expression. I. Gene ontology enrichment analysis was used to analyze the top 20 enriched biological processes among GC patients with high UHMK1 expression. Data information: **P < 0.01, ***P < 0.001, # marked no significance. Download figure Download PowerPoint Click here to expand this figure. Figure EV2. UHMK1 knockdown strongly suppresses GC cell proliferation and invasion A, B. SGC7901 cells were infected with or without shUHMK1-#1, or a shRNA-resistant expression construct, UHMK1Δ. We performed Transwell assays to measure GC cell migration and invasion, respectively. (Left panel) The quantitative number of migrated or invaded cells in shcontrol, shUHMK1-#1, shUHMK1-#1+Vector, and shUHMK1-#1+UHMK1Δ group. Data were presented as mean ± standard deviation from three replicates. Two-tailed statistical significance was assessed by Student's t-test. (Right panel) Representative images of migrated or invaded cells in each group are shown. Scale bars = 100 μm. C. MGC803 cells were transfected with or without shUHMK1-#1, or UHMK1Δ. CCK-8 assay was conducted to explore the biological function of UHMK1 on cell growth. The growth rate was evaluated from Day 1 to Day 6. Data were presented as mean ± standard deviation from three replicates. Two-tailed statistical significance was assessed by Student's t-test. D–F. MGC803 cells were transfected with or without shUHMK1-#1 or UHMK1Δ. Colony formation and Transwell assays were used to measure GC cell proliferation, invasion, and migration, respectively. (Left panel) The quantitative number of colonies, migrated or invaded cells in shcontrol, shUHMK1-#1, shUHMK1-#1+Vector, and shUHMK1-#1+UHMK1Δ group. Data were presented as mean ± standard deviation from three replicates. (Right panel) Representative images of colonies, migrated or invaded cells in each group are shown. Scale bars = 100 μm. G. Western blotting was performed to analyze UHMK1 expression in BGC823 cells transfected with or without UHMK1. CCK-8 assay was conducted to explore the biological function of UHMK1 on cell growth. The growth rate was evaluated from Day 1 to Day 6. Data were presented as mean ± standard deviation from three replicates. Two-tailed statistical significance was assessed by Student's t-test. H, I. BGC823 cells were transfected with or without UHMK1. Colony formation and Transwell assays were used to measure GC cell proliferation, invasion, and migration, respectively. (Left panel) The quantitative number of colonies, migrated or invaded cells in Vector and UHMK1 group. Data were presented as mean ± standard deviation from three replicates. (Right panel) Representative images of colonies, migrated or invaded cells in each group are shown. Scale bars = 100 μm. J. Western blotting was performed to analyze UHMK1 expression in HGC27 cells transfected with or without UHMK1. CCK-8 assay was conducted to explore the biological function of UHMK1 on cell growth. The growth rate was evaluated from Day 1 to Day 6. Data were presented as mean ± standard deviation from three replicates. Two-tailed statistical significance was assessed by Student's t-test. K–M. HGC27 cells were transfected with or without UHMK1. Colony formation and Transwell assays were used to measure GC cell proliferation, invasion, and migration, respectively. (Left panel) The quantitative number of colonies, migrated or invaded cells in Vector and UHMK1 group. Data were presented as mean ± standard deviation from three replicates. (Right panel) Representative images of colonies, migrated or invaded cells in each group are shown. Scale bars = 100 μm. N. NOD/SCID mice (n = 10 per group) were injected subcutaneously with 1.5 × 106 BGC823-vector and BGC823-UHMK1 into opposite flanks. At indicated time points, the xenograft tumors were collected and presented. Scale bars = 5 mm. Data information: Unpaired two-tailed statistical significance was assessed by Student's t-test. *P < 0.05, **P < 0.01, ***P < 0.001, # marked no significance. Download figure Download PowerPoint In vivo, knockdown of UHMK1 significantly decreased GC tumorigenesis and the number of abdominal metastatic nodules compared to these parameters in control mice (Fig 2D–F). However, UHMK1 overexpression significantly promoted GC growth and increased the number of metastatic nodules (Figs EV2N and 2G). To further uncover the function of UHMK1 in GC, we assessed the transcriptomes of GC patients in TCGA with varying levels of UHMK1 expression. And the top 500 differentially expressed genes were analyzed in UHMK1high versus UHMK1low patients (Fig 2H and Appendix Table S3). Gene ontology enrichment analysis indicated that high UHMK1 expression in GC patients might be associated mainly with tumor metabolism (Fig 2I). In summary, UHMK1 upregulation significantly promotes GC growth and metastasis possibly via metabolic pathway reprogramming in tumors. UHMK1 upregulation promotes the invasion and proliferation of GC cells by promoting the de novo purine synthesis pathway To examine whether UHMK1 reprograms GC-associated metabolic pathways, mass spectrometry (MS) was performed to assemble the collect metabolic profiles of SGC7901 cells with or without UHMK1 knockdown. Interestingly, UHMK1 silencing significantly reduced the intracellular pools of purine intermediates and a moderate decrease in pyrimidine metabolites (Appendix Table S4 and Fig 3A and B). Thus, silencing UHMK1 in GC cells primarily inhibits purine biosynthesis. Figure 3. UHMK1 upregulation significantly increases the proliferative and invasive abilities of GC cells by reprogramming purine metabolism A. Schematic representation of the main metabolic pathways. B. LC-MS/MS was used to examine the metabolites in SGC7901 cells with or without UHMK1 knockdown. The data are shown in the heatmap. C. (Upper panel) LC-MS/MS analysis was performed to measure 15N-glutamine-labeled purine synthesis intermediates in BGC823 cells transfected with or without the WT-UHMK1 or UHMK1-K54R constructs. (Lower panel) LC-MS/MS was used to analyze metabolites labeled with 13C-glycine in BGC823 cells transfected with or without the WT-UHMK1 or UHMK1-K54R constructs (three biological replicates). D. RNA and DNA with incorporated 14C-glycine in BGC823 cells transfected with or without the WT-UHMK1 or UHMK1-K54R constructs were examined using LC-MS/MS (three biological replicates). E. qRT–PCR assays were used to analyze the effects of WT-UHMK1 or UHMK1-K54R on the genes controlling purine metabolism. Data were presented as mean ± standard deviation from three replicates. Unpaired two-tailed statistical significance was assessed by Student's t-test. F. UHMK1 silencing significantly decreased SGC7901 cell proliferation, while ATIC overexpression or purine supplementation markedly reversed this inhibition. Data were presented as mean ± standard deviation from three replicates. Unpaired two-tailed statistical significance was assessed by Student's t-test. G. Treatment with the ATIC inhibitor significantly reversed the proliferation of BGC823 cells induced by UHMK1 overexpression. Data were presented as mean ± standard deviation from three replicates. Unpaired two-tailed statistical significance was assessed by Student's t-test. Data information: *P < 0.05, **P < 0.01, ***P < 0.001, # marked no significance. Download figure Download PowerPoint We then used stable isotope-labeled glutamine (amide-15N) to investigate the effect of UHMK1 on purine metabolism (Dayie & Thakur, 2010). Overexpression of wild-type (WT) UHMK1 but not the kinase-dead UHMK1-K54R mutant in BGC823 cells obviously increased the amounts of 15N-purine intermediates (IMP, AMP, and GMP) (Fig 3C upper panel), suggesting that the kinase activity o

Response to Letter to the Editor: NMO 00164‐2017

Several Concerns Arise when the Results Are Interpreted

An Optimized Integrin Α6‐targeted Peptide for Positron Emission Tomography/magnetic Resonance Imaging of Pancreatic Cancer and Its Precancerous Lesion

Induced neural stem/progenitor cell‐derived extracellular vesicles promote recovery post‐stroke

Ruxolitinib Combined with Dexamethasone in Adult Patients with Newly Diagnosed Hemophagocytic Lymphohistiocytosis: A Single‐center Pilot Trial

Severe Septic Shock after Colonoscopic Polypectomy

Guidelines for the Diagnosis and Treatment of Nonalcoholic Fatty Liver Diseases

Novel GNAQ Mutation(r183g) of Port-wine Stains: First Case in East Asia

Whether Cancer Stem Cell Markers Can Serve As the Markers for Malignant Progression of Oral Potentially Malignant Disorders

Reply to the Letter to the Editor by Cantu

Implications of Salivary Mirnas for Noninvasive Diagnosing Oral Potentially Malignant Disorders

Replies to the Letter to the Editor

Investigation of Non‐covalent Interaction of ANF Promoter DNA and Polyamides Containing N‐methylimidazole and N‐methylpyrrole Amino Acids by Electrospray Ionization Mass Spectrometry

Personalized Management for Gorlin‐Goltz Syndrome: Experience of Combination Therapy and Our Algorithm for Treatment

Coronary Plaque Sampling Reveals Molecular Insights Into Coronary Artery Disease

Identification of Candidate Molecular Markers of Nasopharyngeal Carcinoma by Microarray Analysis of Subtracted Cdna Libraries Constructed by Suppression Subtractive Hybridization

Identification of disregulated cell cycle pathway in nasopharyngeal carcinoma by gene set enrichment analysis

UHMK 1 Promotes Gastric Cancer Progression Through Reprogramming Nucleotide Metabolism

Comment on Stereotactic Body Radiation Therapy for Small Primary or Recurrent Hepatocellular Carcinoma—authors’ Reply

Reply to Hernández

Response to Yao's Letter